Pfizer Limited (NSE: PFIZER) submitted its financial results for the quarter ended June 30, 2026 to the National Stock Exchange on July 28, 2026, following a Board Meeting held the same day. The announcement marks the company's first quarterly earnings disclosure for the financial year 2026-27, drawing renewed investor attention to the Mumbai-headquartered pharmaceutical major's performance trajectory and its established dividend distribution record.
Dividend History and Payout Trend
While the Q1 FY27 board meeting outcome did not include a dividend declaration, which is consistent with Pfizer India's practice of announcing dividends at year-end board meetings, the company's historical payout record provides critical context for income-focused investors.
- FY2024: Final dividend of ₹35 per share (350% on face value of ₹10)
- FY2023: Final dividend of ₹35 per share plus a special dividend of ₹5 per share, totalling ₹40 per share (400%), with the special component linked to gains from the sale of its Thane business undertaking
- FY2022: Two tranches declared, including a ₹35 per share final dividend in May 2022 and a ₹30 per share interim dividend in September 2022, aggregating ₹65 per share for the year
- FY2021: Final dividend of ₹35 per share
- FY2020: A special dividend of ₹320 per share declared in April 2020, alongside a final dividend of ₹10 per share in June 2020
- FY2019: Dividend of ₹22.50 per share (225%)
- FY2018: Dividend of ₹20 per share (200%)
Excluding one-time special payouts, the recurring annual dividend has stabilised at ₹35 per share for FY2021, FY2022, FY2023, and FY2024, indicating a consistent baseline payout policy. The FY2023 special dividend and the FY2022 dual-tranche payout were event-driven and are not indicative of a structural increase in the regular dividend.
Dividend Yield Context
With market price and trade data unavailable in the current data set for PFIZER on NSE, a precise dividend yield calculation cannot be provided at this time. Investors should note that at a recurring payout of ₹35 per share, the yield is directly inversely proportional to the prevailing market price. Given the stock's typical trading range in the pharmaceutical large-cap segment, investors are advised to compute yield against the current market price before drawing income comparisons with sector peers.
Company Background
Pfizer Limited is a subsidiary of Pfizer Inc., one of the world's largest biopharmaceutical companies. The Indian listed entity operates across prescription medicines, consumer healthcare, and hospital products. Its ISIN is INE182A01018. The company is regulated by SEBI and its disclosures are governed by SEBI Listing Obligations and Disclosure Requirements (LODR) Regulations.
What This Means for Investors
The submission of Q1 FY27 results signals the start of the earnings season disclosure cycle for Pfizer India. Investors tracking the stock for dividend income should note that the company has maintained a ₹35 per share baseline dividend without interruption for four consecutive financial years from FY2021 through FY2024. The FY2025 dividend announcement, if any, would have been expected around May 2025 and is not reflected in the current data. Any divergence from the ₹35 per share baseline in FY2026 results will be a material signal regarding the company's earnings trajectory and capital allocation priorities. Full Q1 FY27 financial details, including revenue, EBITDA, and net profit, will be available in the detailed financial results filed with the exchange.